2022
DOI: 10.18502/ijph.v51i10.10989
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Breast Cancer Incidence Trends in the Karaganda Region of Kazakhstan

Abstract: Background: The study conducted a component analysis of the dynamics of the incidence of breast cancer (BC) in Karaganda region. Methods: Primary data were for registered patients with BC (ICD 10–C50) in Kazakhstan, Karaganda region the period of 2009-2018. Evaluation of changes in BC incidence in the population of Karaganda was performed using component analysis according to the methodological recommendations. Results: Overall, 4,391 new cases of BC and 1,202 deaths were recorded. The incidence ra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 19 publications
0
1
0
Order By: Relevance
“…The incidence of breast cancer in Kazakhstan is growing (Toguzbayeva et al, 2021;Igissinov et al, 2022). In the study of breast cancer in the ecological regions of from BC per year in the vast majority of regions.…”
Section: Introductionmentioning
confidence: 99%
“…The incidence of breast cancer in Kazakhstan is growing (Toguzbayeva et al, 2021;Igissinov et al, 2022). In the study of breast cancer in the ecological regions of from BC per year in the vast majority of regions.…”
Section: Introductionmentioning
confidence: 99%
“…Notably, Asia had the highest incidence with 1,026,684 cases (45.4%) and the highest number of deaths with 345,559 (50.4%) [1,2]. In Kazakhstan alone, an estimated 4,896 new cases of invasive breast cancer will be diagnosed in 2030 [3]. Moreover, the number of breast cancer-related deaths is set to double by 2040 in many countries, suggesting a concerning escalation in the future burden of BC [4,5].Based on data from the CONCORD-2 study, BC patients diagnosed between 2005 and 2009 had 5-year survival rates of at least 85% [6].…”
mentioning
confidence: 99%